semaglutide russia The Ministry of Health has registered Russia's seventh drug with Weight-loss jab could be made

Tirzepatide's dual GIP/GLP-1 mechanism showed up to 22% weight loss in clinical trials of brand-name tirzepatide

doi: 10.1038/s41569-023-00849-3 46 GongBLiCShiZWangFDaiRChenGet al

Tirzepatide has fewer injection site reactions

Sometimes, it may be the only symptom, or an early symptom

Informed Consent Written informed consent was obtained from the patients parents for data collection and publication of these case reports and accompanying images

As First-Line Treatment Guidelines increasingly support GLP-1 agonists as first-line treatment alongside or instead of metformin: When to consider first-line GLP-1: Established cardiovascular disease High cardiovascular risk Significant obesity (BMI 35+) Strong desire for weight loss Insurance coverage available Traditional metformin-first approach: Lower cost without insurance Decades of safety data Effective for many patients Can add GLP-1 later if needed For many patients, starting with a GLP-1 medication rather than metformin provides superior comprehensive benefit